A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT ID: NCT05040217
Last Updated: 2025-10-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
12 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-02-07
Study Completion Date
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Alzheimer Disease
COMPLETED
PHASE1
Gene Therapy for Alzheimer's Disease Clinical Trial
NCT00017940
Alzheimer Disease
COMPLETED
PHASE1
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
NCT03625622
Mild to Moderate Alzheimer's Disease
COMPLETED
PHASE2
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
NCT00074529
Alzheimer's Disease
COMPLETED
PHASE2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494
Early Alzheimer's Disease
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open label Phase I clinical trial of AAV2-BDNF gene therapy for early Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in 12 participants.
BDNF is a nervous system growth factor that regulates neuronal function in key memory circuits of the brain (the entorhinal cortex and hippocampus). BDNF reduces cell loss, stimulates cell function, and builds new connections (synapses) between brain cells in animal models.
This clinical trial will use techniques of gene therapy because the candidate therapeutic protein, BDNF, does not cross the blood brain barrier (BBB). Two previous clinical programs of Nerve Growth Factor (NGF) gene therapy for AD and Neurturin gene therapy for Parkinson's disease in over 120 patients provided evidence that degenerating neurons respond to growth factors with classic "trophic" responses in the human brain.
Participants will undergo one gene transfer procedure. Thus, dosing is performed only once, and repeat dosing or daily medications are not expected to be required.
12 participants will be enrolled in this Phase I trial, 6 with early AD and 6 with MCI.
BDNF is a nervous system growth factor that regulates neuronal function in key memory circuits of the brain (the entorhinal cortex and hippocampus). BDNF reduces cell loss, stimulates cell function, and builds new connections (synapses) between brain cells in animal models.
This clinical trial will use techniques of gene therapy because the candidate therapeutic protein, BDNF, does not cross the blood brain barrier (BBB). Two previous clinical programs of Nerve Growth Factor (NGF) gene therapy for AD and Neurturin gene therapy for Parkinson's disease in over 120 patients provided evidence that degenerating neurons respond to growth factors with classic "trophic" responses in the human brain.
Participants will undergo one gene transfer procedure. Thus, dosing is performed only once, and repeat dosing or daily medications are not expected to be required.
12 participants will be enrolled in this Phase I trial, 6 with early AD and 6 with MCI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer's Disease
Mild Cognitive Impairment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
This study aims to reduce neuronal loss and rebuild synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). A total of 12 subjects will be enrolled: subjects 1-6 will have a diagnosis of AD and subjects 7-12 will have a diagnosis of MCI. The gene therapy vector will consist of adeno-associated virus serotype 2 (AAV2) and will be stereotaxically administered into the brain under MRI guidance. Subjects will be followed over a pre-determined study time duration of 24 months, and indefinitely thereafter.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gene transfer of AAV2-BDNF
Up to 12 subjects will receive open-label AAV2-BDNF
Group Type
EXPERIMENTAL
AAV2-BDNF Gene Therapy
Intervention Type
GENETIC
AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
AAV2-BDNF Gene Therapy
Intervention Type
BIOLOGICAL
Gene therapy is a biological therapy delivering the BDNF gene to the brain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AAV2-BDNF Gene Therapy
AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
Intervention Type
GENETIC
AAV2-BDNF Gene Therapy
Gene therapy is a biological therapy delivering the BDNF gene to the brain
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Growth Factor Gene Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Diagnosis of dementia due to Alzheimer's Disease (AD) by National Institute of Aging (NIA) - Alzheimer's Association (AA) criteria for AD 15. The diagnosis of probable AD according to NIA criteria 15 is internationally recognized as the "gold standard" for diagnosing AD.
2. Mini-Mental State Exam score between 22 and 28 (inclusive).
3. No significant cerebral vascular disease: modified Hachinski score of ≤ 4.
4. Age 50 - 80 years old.
5. EEG is free of epileptiform abnormalities.
6. Permitted medications stable for at least one month prior to screening. In particular:
1. Subjects taking stable doses of antidepressants lacking significant anti-cholinergic side effects are acceptable (if they are not currently depressed and do not have a history of major depression within the past two years).
2. Estrogen-replacement therapy is permissible.
3. Anti-cholinesterases and memantine are allowed (stable doses for preceding 3 months).
7. Geriatric Depression Rating scale indicates no depression (Geriatric Depression Scale not greater than 8 on GDS-30).
8. A caregiver is available who has frequent contact with the subject (e.g., an average of ten hours/week or more), agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol.
9. CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal (e.g., subdural hematomas) or generalized lesions (e.g., hydrocephalus) and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area that is not believed to contribute to the cognitive impairment is permissible.
10. Adequate visual and auditory acuity to allow neuropsychological testing that requires visual and auditory acuity.
11. Good general health with no additional diseases expected to interfere with the study in the opinion of the investigator.
12. Normal serum B12, RPR, and thyroid function tests; or clinically insignificant abnormalities that would not be expected to interfere with the study.
13. ECG without clinically significant abnormalities that would be expected to interfere with the study.
14. Subject is not pregnant, lactating, or of child-bearing potential (i.e., women must be post-menopausal or surgically sterile).
1. Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer's Disease by NIA-AA criteria 16. The diagnosis of MCI is also internationally recognized as the current standard for diagnosing MCI.
2. Mini-Mental State Exam score between 24 and 29 (inclusive) and examination consistent with diagnosis of MCI. We will not require CSF biomarkers for subclassifying MCI risk of progression to AD.
3. No significant cerebral vascular disease: modified Hachinski score of ≤ 4.
4. Minimum age 50.
5. EEG is free of epileptiform abnormalities.
6. Permitted medications stable for at least one month prior to screening. In particular:
1. Subjects taking stable doses of antidepressants lacking significant anti-cholinergic side effects are acceptable (if they are not currently depressed and do not have a history of major depression within the past two years).
2. Estrogen-replacement therapy is permissible.
3. Anti-cholinesterases and memantine are allowed (stable doses for preceding 3 months).
7. Geriatric Depression Rating scale indicates no depression (Geriatric Depression Scale not greater than 8 on GDS-30).
8. A caregiver is available who has frequent contact with the subject (e.g., an average of ten hours/week or more), agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol.
9. CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal (e.g., subdural hematomas) or generalized lesions (e.g., hydrocephalus) and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area that is not believed to contribute to the cognitive impairment is permissible.
10. Adequate visual and auditory acuity to allow neuropsychological testing that was a visual and auditory acuity.
11. Good general health with no additional diseases expected to interfere with the study in the opinion of the investigator.
12. Normal serum B12, RPR, and thyroid function tests; or clinically insignificant abnormalities that would not be expected to interfere with the study.
13. ECG without clinically significant abnormalities that would be expected to interfere with the study.
14. Subject is not pregnant, lactating, or of child-bearing potential (i.e., women must be post-menopausal or surgically sterile).
2. Mini-Mental State Exam score between 22 and 28 (inclusive).
3. No significant cerebral vascular disease: modified Hachinski score of ≤ 4.
4. Age 50 - 80 years old.
5. EEG is free of epileptiform abnormalities.
6. Permitted medications stable for at least one month prior to screening. In particular:
1. Subjects taking stable doses of antidepressants lacking significant anti-cholinergic side effects are acceptable (if they are not currently depressed and do not have a history of major depression within the past two years).
2. Estrogen-replacement therapy is permissible.
3. Anti-cholinesterases and memantine are allowed (stable doses for preceding 3 months).
7. Geriatric Depression Rating scale indicates no depression (Geriatric Depression Scale not greater than 8 on GDS-30).
8. A caregiver is available who has frequent contact with the subject (e.g., an average of ten hours/week or more), agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol.
9. CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal (e.g., subdural hematomas) or generalized lesions (e.g., hydrocephalus) and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area that is not believed to contribute to the cognitive impairment is permissible.
10. Adequate visual and auditory acuity to allow neuropsychological testing that requires visual and auditory acuity.
11. Good general health with no additional diseases expected to interfere with the study in the opinion of the investigator.
12. Normal serum B12, RPR, and thyroid function tests; or clinically insignificant abnormalities that would not be expected to interfere with the study.
13. ECG without clinically significant abnormalities that would be expected to interfere with the study.
14. Subject is not pregnant, lactating, or of child-bearing potential (i.e., women must be post-menopausal or surgically sterile).
1. Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer's Disease by NIA-AA criteria 16. The diagnosis of MCI is also internationally recognized as the current standard for diagnosing MCI.
2. Mini-Mental State Exam score between 24 and 29 (inclusive) and examination consistent with diagnosis of MCI. We will not require CSF biomarkers for subclassifying MCI risk of progression to AD.
3. No significant cerebral vascular disease: modified Hachinski score of ≤ 4.
4. Minimum age 50.
5. EEG is free of epileptiform abnormalities.
6. Permitted medications stable for at least one month prior to screening. In particular:
1. Subjects taking stable doses of antidepressants lacking significant anti-cholinergic side effects are acceptable (if they are not currently depressed and do not have a history of major depression within the past two years).
2. Estrogen-replacement therapy is permissible.
3. Anti-cholinesterases and memantine are allowed (stable doses for preceding 3 months).
7. Geriatric Depression Rating scale indicates no depression (Geriatric Depression Scale not greater than 8 on GDS-30).
8. A caregiver is available who has frequent contact with the subject (e.g., an average of ten hours/week or more), agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol.
9. CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal (e.g., subdural hematomas) or generalized lesions (e.g., hydrocephalus) and without clinical symptoms suggestive of intervening neurological disease. A lacune in a non-critical brain area that is not believed to contribute to the cognitive impairment is permissible.
10. Adequate visual and auditory acuity to allow neuropsychological testing that was a visual and auditory acuity.
11. Good general health with no additional diseases expected to interfere with the study in the opinion of the investigator.
12. Normal serum B12, RPR, and thyroid function tests; or clinically insignificant abnormalities that would not be expected to interfere with the study.
13. ECG without clinically significant abnormalities that would be expected to interfere with the study.
14. Subject is not pregnant, lactating, or of child-bearing potential (i.e., women must be post-menopausal or surgically sterile).
Exclusion Criteria
1. Any significant neurological disease other than suspected incipient disease; i.e., seizure disorder, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, arteriovenous malformation or history of significant head trauma followed by persistent neurologic deficits or known structural abnormalities.
2. Individual has symptoms of aphasia which would make administration of study assessments and collection of information during study challenging.
3. Major depression or another major psychiatric disorder as described in DMS-IV within the past two years.
4. Psychotic features, agitation or behavioral problems within the last three months which could lead to difficulty in cooperating with study.
5. History of alcohol or substance abuse or dependence within the past two years (DMS-IV criteria).
6. History of schizophrenia (DMS-IV criteria).
7. Affirms suicidal ideation in response to questions number 4 or 5 in the C-SSRS during the past 3 months (i.e., "active suicidal ideation with some intent to act, without specific plan" or "active suicidal ideation with specific plan and intent") or affirms any of the questions contained in the Suicidal Behavior section of the C-SSRS as applicable during the past 12 months.
8. History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
9. Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol including:
1. History of myocardial infarction in the past year or unstable or severe cardiovascular disease including angina or congestive heart failure with symptoms at rest.
2. Clinically significant obstructive pulmonary disease or asthma.
3. Clinically significant and unstable gastrointestinal disorder; i.e., ulcer disease or history of active or occult gastrointestinal bleeding within two years.
4. Clinically significant test abnormalities on the battery of screening tests (hematology, prothrombin time, chemistry, urinalysis, ECG).
5. Insulin-requiring diabetes or uncontrolled diabetes mellitus.
6. Uncontrolled hypertension (systolic blood pressure greater than 180 or diastolic blood pressure greater than 110).
7. History of clinically significant liver disease, coagulopathy, or Vitamin K deficiency within the past two years.
8. History of uncorrected hypothyroidism.
10. Excluded Medications
1. Use of centrally active beta-blockers, narcotics, methyldopa, or clonidine within four weeks prior to screening.
2. Use of anti-Parkinsonian medications (e.g., Sinemet®, amantadine, bromocriptine, pergolide and selegiline) within two months prior to screening.
3. Use of neuroleptics or narcotic analgesics within four weeks prior to screening.
4. Use of long-acting benzodiazepines or barbiturates within four weeks prior to screening.
5. Use of short-acting anxiolytic or sedative hypnotics more frequently than two times per week within four weeks prior to screening (note: sedative agents should not be used within 72 hours of screening).
6. Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the four weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable).
7. Use of systemic corticosteroids within three months prior to screening.
8. Use of medication with significant cholinergic or anticholinergic side effects (e.g., pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within four weeks prior to screening.
9. Use of anticonvulsants (phenytoin, phenobarbital, carbamazepine, valproate) within two months prior to screening.
10. Use of anticoagulant therapy within four weeks prior to screening.
11. Use of Anti-amyloid monoclonal antibodies not permissible within 1 month of Treatment (Day 0) Vector Delivery.
11. Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to Treatment (Day 0) Vector Delivery.
12. Any contraindication for undergoing MRI (e.g., pacemakers, epicardial pacer wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prosthesis, implants with potential magnetic properties, metallic bodies in the eyes, etc.) or contraindication to receiving gadolinium and other imaging contrast agents.
13. Subjects who, in the investigators' opinion, will not comply with study procedures.
14. Any history of gene therapy to include RNA or DNA targeted Alzheimer's Disease specific investigational agents.
2. Individual has symptoms of aphasia which would make administration of study assessments and collection of information during study challenging.
3. Major depression or another major psychiatric disorder as described in DMS-IV within the past two years.
4. Psychotic features, agitation or behavioral problems within the last three months which could lead to difficulty in cooperating with study.
5. History of alcohol or substance abuse or dependence within the past two years (DMS-IV criteria).
6. History of schizophrenia (DMS-IV criteria).
7. Affirms suicidal ideation in response to questions number 4 or 5 in the C-SSRS during the past 3 months (i.e., "active suicidal ideation with some intent to act, without specific plan" or "active suicidal ideation with specific plan and intent") or affirms any of the questions contained in the Suicidal Behavior section of the C-SSRS as applicable during the past 12 months.
8. History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
9. Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol including:
1. History of myocardial infarction in the past year or unstable or severe cardiovascular disease including angina or congestive heart failure with symptoms at rest.
2. Clinically significant obstructive pulmonary disease or asthma.
3. Clinically significant and unstable gastrointestinal disorder; i.e., ulcer disease or history of active or occult gastrointestinal bleeding within two years.
4. Clinically significant test abnormalities on the battery of screening tests (hematology, prothrombin time, chemistry, urinalysis, ECG).
5. Insulin-requiring diabetes or uncontrolled diabetes mellitus.
6. Uncontrolled hypertension (systolic blood pressure greater than 180 or diastolic blood pressure greater than 110).
7. History of clinically significant liver disease, coagulopathy, or Vitamin K deficiency within the past two years.
8. History of uncorrected hypothyroidism.
10. Excluded Medications
1. Use of centrally active beta-blockers, narcotics, methyldopa, or clonidine within four weeks prior to screening.
2. Use of anti-Parkinsonian medications (e.g., Sinemet®, amantadine, bromocriptine, pergolide and selegiline) within two months prior to screening.
3. Use of neuroleptics or narcotic analgesics within four weeks prior to screening.
4. Use of long-acting benzodiazepines or barbiturates within four weeks prior to screening.
5. Use of short-acting anxiolytic or sedative hypnotics more frequently than two times per week within four weeks prior to screening (note: sedative agents should not be used within 72 hours of screening).
6. Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the four weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable).
7. Use of systemic corticosteroids within three months prior to screening.
8. Use of medication with significant cholinergic or anticholinergic side effects (e.g., pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within four weeks prior to screening.
9. Use of anticonvulsants (phenytoin, phenobarbital, carbamazepine, valproate) within two months prior to screening.
10. Use of anticoagulant therapy within four weeks prior to screening.
11. Use of Anti-amyloid monoclonal antibodies not permissible within 1 month of Treatment (Day 0) Vector Delivery.
11. Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to Treatment (Day 0) Vector Delivery.
12. Any contraindication for undergoing MRI (e.g., pacemakers, epicardial pacer wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prosthesis, implants with potential magnetic properties, metallic bodies in the eyes, etc.) or contraindication to receiving gadolinium and other imaging contrast agents.
13. Subjects who, in the investigators' opinion, will not comply with study procedures.
14. Any history of gene therapy to include RNA or DNA targeted Alzheimer's Disease specific investigational agents.
Minimum Eligible Age
50 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University
OTHER
Sponsor Role
collaborator
Mark Tuszynski
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mark Tuszynski
Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Tuszynski, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - San Diego
La Jolla, California, United States
Site Status
RECRUITING
The Ohio State University
Columbus, Ohio, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009 Mar;15(3):331-7. doi: 10.1038/nm.1912. Epub 2009 Feb 8.
Reference Type
RESULT
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011 Mar;10(3):209-19. doi: 10.1038/nrd3366.
Reference Type
RESULT
Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, Koo EH, Masliah E, Tuszynski MH. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013 Sep 25;33(39):15596-602. doi: 10.1523/JNEUROSCI.5195-12.2013.
Reference Type
RESULT
Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH. Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. JAMA Neurol. 2015 Oct;72(10):1139-47. doi: 10.1001/jamaneurol.2015.1807.
Reference Type
RESULT
Tuszynski MH. Growth Factor Gene Therapy for Alzheimer's Disease. J Alzheimers Dis. 2024;101(s1):S433-S441. doi: 10.3233/JAD-240545.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCSD-BDNF1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420
COMPLETED
PHASE2
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890
RECRUITING
PHASE1/PHASE2
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
NCT02600130
COMPLETED
PHASE1
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733
COMPLETED
PHASE1/PHASE2
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
NCT02833792
UNKNOWN
PHASE2
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
RECRUITING
PHASE2/PHASE3
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936
COMPLETED
PHASE2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
NCT04623242
COMPLETED
PHASE2/PHASE3
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
NCT05602727
TERMINATED
PHASE2
Impact of a Biophoton Therapy on Patients With Brain Disorders
NCT06147999
RECRUITING
NA
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939
TERMINATED
PHASE1
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923
COMPLETED
PHASE2
The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
NCT04250376
UNKNOWN
NA
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
COMPLETED
PHASE1
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
NCT01852110
TERMINATED
PHASE2
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
RECRUITING
PHASE2
Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease
NCT07205601
NOT_YET_RECRUITING
PHASE2
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT02565511
TERMINATED
PHASE2/PHASE3
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
NCT01626391
TERMINATED
PHASE2
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157
RECRUITING
PHASE2/PHASE3
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
NCT05476783
TERMINATED
PHASE2
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
NCT06964230
NOT_YET_RECRUITING
PHASE2/PHASE3
Neurostimulation for Cognitive Enhancement in Alzheimer's Disease
NCT04404153
ACTIVE_NOT_RECRUITING
NA
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
NCT02079909
COMPLETED
PHASE2